NEOG Reports $211.2M Q3 Rev, $17M Net Loss, Adjusted EPS $0.09, $48.2M Adjusted EBITDA, Divest Genomics, Raise FY26 Outlook
Neogen Corp · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $8.92
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS